HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Skin stripping not yet viable replacement for comparative clinical trials -- FDA cmte.

This article was originally published in The Rose Sheet

Executive Summary

SKIN STRIPPING SHOULD NOT REPLACE TOPICAL CLINICAL BIO STUDIES for topical generic drug products because dermatopharmacokinetics "is very risky without more validation," and "I do not think it is time to use [DPK] as a replacement" for in vivo comparative clinical trials, committee member Lynn Drake, MD, University of Oklahoma, said at FDA's Dermatologic & Ophthalmic Drugs Advisory Committee meeting March 20 in Gaithersburg, Md. Speaking for the committee, Drake said she is "unwilling to accept this test as a replacement for what we do in patients and see in patients."
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS005297

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel